Chinese Journal of Mycology 2021, Vol. 16 Issue (3): 188-193,210.
Previous Articles Next Articles
Received:2020-12-24
Online:2021-06-28
Published:2021-06-28
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/
http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/Y2021/V16/I3/188
| [1] Sun Y, Huang H, Chen J, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China[J]. Tumour Biol,2015,36(2):757-767. [2] Ostrosky-Zeichner L, Al-Obaidi M. Invasive fungal infections in the intensive care unit[J]. Infect Dis Clin North Am,2017,31(3):475-487. [3] von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection[J]. Dtsch Arztebl Int,2019,116(16):271-278. [4] Baginski M, Resat H, Borowski E. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels[J]. Biochim Biophys Acta,2002,1567(1-2):63-78. [5] Gray KC, Palacios D S, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol[J]. Proc Natl Acad Sci U S A,2012,109(7):2234-2239. [6] Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge[J]. Nat Chem Biol,2014,10(5):400-406. [7] Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs[J]. Clin Pharmacokinet,1983,8(1):17-42. [8] Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans[J]. Antimicrob Agents Chemother,2002,46(3):828-833. [9] Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate[J]. Antimicrob Agents Chemother,2002,46(3):834-840. [10] Ridente Y, Aubard J, Bolard J. Absence in amphotericin B-spiked human plasma of the free monomeric drug, as detected by SERS[J]. FEBS Lett,1999,446(2-3):283-286. [11] Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients[J]. Infection,2017,45(6):737-779. [12] Collette N, van der Auwera P, Lopez AP, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate[J]. Antimicrob Agents Chemother,1989,33(3):362-368. [13] Atkinson AJ, Bindschadler DD. Pharmacokinetics of intrathecally administered amphotericin B[J]. Am Rev Respir Dis,1969,99(6):917-924. [14] Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics[J]. Curr Clin Pharmacol,2007,2(1):37-58. [15] Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans[J]. Antimicrob Agents Chemother,1978,13(2):271-276. [16] Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds[J]. Infect Dis Clin North Am,2003,17(1):159-191. [17] Polak A. Pharmacokinetics of amphotericin B and flucytosine[J]. Postgrad Med J,1979,55(647):667-670. [18] Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal[J]. Pediatr Infect Dis J,1997,16(9):885-894. [19] Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective agents during lactation, Part 3: Antivirals, antifungals, and urinary antiseptics[J]. J Hum Lact,2001,17(2):160-166. [20] Ilett KF, Kristensen JH. Drug use and breastfeeding[J]. Expert Opin Drug Saf,2005,4(4):745-768. [21] Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children[J]. Antimicrob Agents Chemother,1989,33(11):1989-1993. [22] Nath CE, Mclachlan AJ, Shaw PJ, et al. Amphotericin B dose optimization in children with malignant diseases[J]. Chemotherapy,2007,53(2):142-147. [23] Downes KJ, Fisher BT, Zane NR. Administration and dosing of systemic antifungal agents in pediatric patients[J]. Paediatr Drugs,2020,22(2):165-188. [24] Starke JR, Mason EJ, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children[J]. J Infect Dis,1987,155(4):766-774. [25] Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates[J]. J Pediatr,1990,116(5):791-797. [26] Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B[J]. J Infect Dis,1969,120(4):427-436. [27] Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion[J]. Antimicrob Agents Chemother,1985,27(5):868-871. [28] Block ER, Bennett J E, Livoti LG, et al. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man[J]. Ann Intern Med,1974,80(5):613-617. [29] Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis[J]. Am J Kidney Dis,2001,37(6):E45. [30] Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration[J]. J Antimicrob Chemother,2003,51(3):671-681. [31] Craven PC, Ludden TM, Drutz DJ, et al. Excretion pathways of amphotericin B[J]. J Infect Dis,1979,140(3):329-341. [32] Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature[J]. Clin Ther,2016,38(9):1976-1994. [33] Botero AJ, Restrepo HA. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function[J]. Cochrane Database Syst Rev,2015(11):D10481. [34] Steimbach LM, Tonin FS, Virtuoso S, et al. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis[J]. Mycoses,2017,60(3):146-154. [35] Deray G. Amphotericin B nephrotoxicity[J]. J Antimicrob Chemother,2002,49 (Suppl 1):37-41. [36] Bullock WE, Luke RG, Nuttall CE, et al. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys[J]. Antimicrob Agents Chemother,1976,10(3):555-563. [37] Ellis ME, Al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B[J]. Antimicrob Agents Chemother,1992,36(1):172-179. [38] Hasnain MG, Nath P, Maruf S, et al. Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study[J]. BMC Res Notes,2018,11(1):918. [39] Meiring S, Fortuin-De SM, Kularatne R, et al. Prevalence and hospital management of amphotericin B deoxycholate-related toxicities during treatment of HIV-associated cryptococcal meningitis in South Africa[J]. PLoS Negl Trop Dis,2016,10(7):e4865. [40] Horwitz E, Shavit O, Shouval R, et al. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions[J]. Int J Clin Pharm,2012,34(4):611-617. [41] Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group[J]. N Engl J Med,1999,340(10):764-771. [42] Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group[J]. Am J Med,1989,86(6 Pt 1):668-672. [43] Ahimbisibwe C, Kwizera R, Ndyetukira JF, et al. Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study[J]. BMC Infect Dis,2019,19(1):558. [44] Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis,2016,63(4):e1-e60. [45] Marra F, Partovi N, Wasan KM, et al. Amphotericin B disposition after aerosol inhalation in lung transplant recipients[J]. Ann Pharmacother,2002,36(1):46-51. [46] Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients[J]. Transplantation,2003,75(9):1571-1574. [47] Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma[J]. Eur Respir J,1995,8(8):1263-1268. [48] Ho J, Fowler P, Heidari A, et al. Intrathecal amphotericin B: a 60-year experience in treating coccidioidal meningitis[J]. Clin Infect Dis,2017,64(4):519-524. [49] Kan VL, Bennett JE, Amantea MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers[J]. J Infect Dis,1991,164(2):418-421. [50] Hoeprich PD. Elimination half-life of amphotericin B[J]. J Infect,1990,20(2):173-175. [51] Ayestaran A, Lopez RM, Montoro JB, et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia[J]. Antimicrob Agents Chemother,1996,40(3):609-612. [52] Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients[J]. Antimicrob Agents Chemother,1997,41(6):1275-1280. [53] Starke JR, Mason EJ, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children[J]. J Infect Dis,1987,155(4):766-774. [54] Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children[J]. J Pediatr,1988,113(3):559-563. [55] Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis[J]. Am J Kidney Dis,2001,37(6):E45. [56] Lawrence RM, Hoeprich PD, Jagdis FA, et al. Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate, Macaca mulatta[J]. J Antimicrob Chemother,1980,6(2):241-249. [57] van Etten EW, Otte-Lambillion M, van Vianen W, et al. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans[J]. J Antimicrob Chemother,1995,35(4):509-519. |
| [1] | XU Xue, DENG Shuwen, WANG Xiaodong, ZHAO Rongfen, ZHANG Hong, YU Nong, Mohammad Javad Najafzadeh, SHI Dongmei, LU Min. Species identification and in vitro antifungal susceptibility profile of 39 isolates of Aspergillus section Flavi isolated from nails in Iran [J]. Chinese Journal of Mycology, 2021, 16(4): 222-228. |
| [2] | . [J]. Chinese Journal of Mycology, 2021, 16(4): 257-261. |
| [3] | . [J]. Chinese Journal of Mycology, 2021, 16(4): 262-265. |
| [4] | QIU Lijuan, CHAO Wen, SHI Anzhe, YAN Lan, LYU Quanzhen, JIANG Yuanying. Study on the synergistic antifungal activity of glyceryl monostearate and caspofungin in vitro [J]. Chinese Journal of Mycology, 2021, 16(3): 145-149,165. |
| [5] | ZHANG Xinyu, PAN Kaisu, LUO Hong, ZHENG Dongyan, ZHENG Yanqin, CAO Cunwei, LIANG Gang. In vitro susceptibility of berberine combined with antifungal agents against Talaromyces marneffei [J]. Chinese Journal of Mycology, 2021, 16(3): 176-181. |
| [6] | Expert group of consensus on the clinical application of Terbinafine. Clinical Application of Terbinafine：Expert consensus [J]. Chinese Journal of Mycology, 2020, 15(5): 257-261. |
| [7] | ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of superficial mycosis [J]. Chinese Journal of Mycology, 2020, 15(5): 297-303. |
| [8] | QU Xin-yao, LI Shan-shan, QU Yue, Abdulhakim Salad Nageye, SONG Yang, CUI Yan. In vitro antifungal susceptibility of 10 Chinese herbal monomers against Sporothrix globosa [J]. Chinese Journal of Mycology, 2020, 15(3): 145-149. |
| [9] | . [J]. Chinese Journal of Mycology, 2020, 15(3): 179-182. |
| [10] | ZHANG Juan, LI Xiao-hui, Feng Xue-ling, ZHANG Jing-jing. Study on the antifungal effect of Aspergillus fumigatus, Trichophyton mentogrophtes and Cryptococcus neoformans to alkaloids from Sophora alopecuroides [J]. Chinese Journal of Mycology, 2020, 15(2): 72-77. |
| [11] | LIU Guang-rong, ZHAI Chun-tao, JIN Min-rong, LI Cheng-liang. The inhibitory effects of natural antibacterial agent on 5 pathogenic microorganisms [J]. Chinese Journal of Mycology, 2020, 15(2): 88-92. |
| [12] | TAN Jing-wen, XU Hong, SONG Jin-feng, GAO Zhi-qin, YANG Hong, YANG Lian-juan, WEN Hai. In vitro antifungal susceptibility of polyhexamethylene biguanide against common superficial fungal species [J]. Chinese Journal of Mycology, 2020, 15(2): 93-96. |
| [13] | ZHU Hong-mei, WEN Hai, LI Bin. Advance on Traditional Chinese Herb in the topical antifungal therapy [J]. Chinese Journal of Mycology, 2019, 14(5): 316-320. |
| [14] | YU Shu-ying, ZHANG Li, LI Ying, XU Ying-chun. Evaluation of the in vitro antifungal activity of the domestic caspofungin against clinical Aspergillus isolates [J]. Chinese Journal of Mycology, 2019, 14(3): 141-146. |
| [15] | LIU Fei-fei, WANG Yan, CHEN Rong, SHEN Jian-zhen. Clinical efficacy and safety of intravenous injection voriconazole and fluconazole in preventing fungal infection in China: A meta analysis [J]. Chinese Journal of Mycology, 2019, 14(3): 159-163. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
